#	Pagina
attuale pagina	/open-h2020/projects/207222/index.html
-1	/open-h2020/projects/227440/index.html
-2	/open-h2020/projects/208977/index.html
-3	/open-h2020/projects/225715/index.html
-4	/open-fp7/projects/108382/index.html
-5	/open-h2020/projects/206320/index.html
-6	/open-h2020/projects/219263/index.html
-7	/open-h2020/projects/204899/index.html
-8	/open-fp7/projects/185456/index.html
-9	/open-h2020/projects/205129/index.html
-10	/open-h2020/projects/221098/index.html

Opendata, web and dolomites

RABYD-VAX SIGNED

Development of a Next-Generation, Dual-Target Rabies/Flavivirus Infectious DNA (iDNA) Vaccine

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

RABYD-VAX project word cloud

Explore the words cloud of the RABYD-VAX project. It provides you a very rough idea of what is the project "RABYD-VAX" about.

micro vector japanese outbreaks antigens deadliest administered sufficient protection efficient protective stability commercial die prophylactic platform yf launches injection combine fatality needle rhesus zika yellow macaques danger customize benefits 30 hamsters plasmid induction likewise annually candidates 58 existence medical chain yearly dose safe thermo animal disease prequalification employ despite paediatric free thermostable naked rabies unvaccinated virus small life yfv compliance express cold excellent encephalitis routine infectious earth vaccine cheap vaccination ease doses people models fever vaccines live demonstrated clinical tech dual uncontrollable chimeric lethal regulatory half dna children proprietary p01a idna protects rate 9 99 10 attenuated versatile immunity mice

Project "RABYD-VAX" data sheet

The following table provides information about the project.

Coordinator	KATHOLIEKE UNIVERSITEIT LEUVEN Organization address address: OUDE MARKT 13 city: LEUVEN postcode: 3000 website: www.kuleuven.be contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Belgium [BE]
Project website	https://rabyd-vax.eu/
Total cost	4˙113˙385 €
EC max contribution	4˙113˙385 € (100%)
Programme	1. H2020-EU.3.1.2. (Preventing disease)
Code Call	H2020-SC1-2016-RTD
Funding Scheme	RIA
Starting year	2017
Duration (year-month-day)	from 2017-01-01 to 2020-12-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	KATHOLIEKE UNIVERSITEIT LEUVEN KATHOLIEKE UNIVERSITEIT LEUVEN Organization address address: OUDE MARKT 13 city: LEUVEN postcode: 3000 website: www.kuleuven.be contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	BE (LEUVEN)	coordinator	1˙818˙113.00
2	THE SECRETARY OF STATE FOR ENVIRONMENT, FOOD AND RURAL AFFAIRS THE SECRETARY OF STATE FOR ENVIRONMENT, FOOD AND RURAL AFFAIRS Organization address address: Area 1A, Nobel House, Smith Square 17 city: LONDON postcode: SW1P 3JR website: www.defra.gov.uk contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UK (LONDON)	participant	827˙107.00
3	STICHTING BIOMEDICAL PRIMATE RESEARCH CENTER STICHTING BIOMEDICAL PRIMATE RESEARCH CENTER Organization address address: LANGE KLEIWEG 161 city: RIJSWIJK ZH postcode: 2288 GJ website: www.bprc.nl contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NL (RIJSWIJK ZH)	participant	818˙458.00
4	SCIENSANO SCIENSANO Organization address address: JULIETTE WYTSMANSTRAAT 14 city: ELSENE postcode: 1050 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	BE (ELSENE)	participant	649˙705.00
5	INSTITUT SCIENTIFIQUE DE SANTE PUBLIQUE INSTITUT SCIENTIFIQUE DE SANTE PUBLIQUE Organization address address: Rue Juliette Wytsman 14 city: BRUXELLES postcode: 1050 website: www.iph.fgov.be contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	BE (BRUXELLES)	participant	0.00

Map

Project objective

Rabies is the deadliest disease on earth (99.9% fatality rate). Annually, ~58.000 people die from rabies, more than half of them are children. Many remain unvaccinated because of the high costs and the need for a cold-chain. Likewise, despite the existence of an excellent yellow fever (YF) vaccine, yearly ~30.000 people die of YF. The 80-year old low-tech production process does not allow to produce sufficient doses. There is now a real danger that major YF-outbreaks become uncontrollable. We aim at developing an efficient, safe, cheap, thermostable and easy-to-produce vaccine that can be needle-free administered, that protects against both rabies and YF, and that can be implemented in routine prophylactic paediatric vaccination. For this, we will employ our (P01a) proprietary infectious DNA (iDNA) vaccine technology. Simple, even needle-free injection of a low dose (1-10µg) of this easy-to-produce naked plasmid in mice and hamsters launches the YF vaccine virus and protects hamsters as efficiently as the commercial vaccine against lethal YF challenge. The iDNA YF vaccine will be used as vector to express relevant protective rabies antigens. Dual protection of such chimeric iDNA rabies/YF vaccine will be demonstrated against lethal rabies and YFV challenge in small animal models. Likewise, chimeric rabies/Japanese encephalitis and rabies/Zika virus iDNA vaccine candidates will be generated using this versatile platform. Next, induction of protective immunity will be demonstrated in rhesus macaques. The iDNA vaccines combine the benefits of both the YF live-attenuated vaccine (highly efficient life-long induction of immunity) and the thermo-stability, ease-of-production and the potential to customize (in response to emerging medical needs) of “classical” DNA vaccines. A path towards advanced pre-clinical and clinical development of such novel vaccines will be developed in compliance with European regulatory and WHO prequalification requirements.

Deliverables

List of deliverables.
Dissemination and Communication Measures	Documents, reports	2019-05-31 16:34:02

Take a look to the deliverables list in detail: detailed list of RABYD-VAX deliverables.

Publications

List of publications.
year	authors and title	journal	last update
2019	Rebecca Shipley, Edward Wright, David Selden, Guanghui Wu, James Aegerter, Anthony R Fooks, Ashley C Banyard Bats and Viruses: Emergence of Novel Lyssaviruses and Association of Bats with Viral Zoonoses in the EU published pages: 31, ISSN: 2414-6366, DOI: 10.3390/tropicalmed4010031	Tropical Medicine and Infectious Disease 4/1	2020-03-11
2018	DieudonnÃ© B. Kum, Niraj Mishra, Robbert Boudewijns, Ivan Gladwyn-Ng, Christian Alfano, Ji Ma, Michael A. Schmid, Rafael E. Marques, Dominique Schols, Suzanne Kaptein, Laurent Nguyen, Johan Neyts, Kai Dallmeier A yellow feverâ€“Zika chimeric virus vaccine candidate protects against Zika infection and congenital malformations in mice published pages: , ISSN: 2059-0105, DOI: 10.1038/s41541-018-0092-2	npj Vaccines 3/1	2020-03-11
2018	Ashley C. Banyard, David Selden, Guanghui Wu, Leigh Thorne, Daisy Jennings, Denise Marston, Stefan Finke, Conrad M. Freuling, Thomas MÃ¼ller, Juan E. EchevarrÃa, Anthony R. Fooks Isolation, antigenicity and immunogenicity of Lleida bat lyssavirus published pages: 1590-1599, ISSN: 0022-1317, DOI: 10.1099/jgv.0.001068	Journal of General Virology 99/12	2020-03-11
2019	DieudonnÃ© Buh Kum, Niraj Mishra, Bram Vrancken, Hendrik Jan Thibaut, Annelies Wilder-Smith, Philippe Lemey, Johan Neyts, Kai Dallmeier Limited evolution of the yellow fever virus 17d in a mouse infection model published pages: 1734-1746, ISSN: 2222-1751, DOI: 10.1080/22221751.2019.1694394	Emerging Microbes & Infections 8/1	2020-03-11
2019	Samuel P. Smith, Guanghui Wu, Anthony R. Fooks, Julian Ma, Ashley C. Banyard Trying to treat the untreatable: experimental approaches to clear rabies virus infection from the CNS published pages: 1171-1186, ISSN: 0022-1317, DOI: 10.1099/jgv.0.001269	Journal of General Virology 100/8	2020-03-11
2018	Jennifer Evans, Guanghui Wu, David Selden, Hubert Buczkowski, Leigh Thorne, Anthony Fooks, Ashley Banyard Utilisation of Chimeric Lyssaviruses to Assess Vaccine Protection against Highly Divergent Lyssaviruses published pages: 130, ISSN: 1999-4915, DOI: 10.3390/v10030130	Viruses 10/3	2019-06-11
2018	E. Kip, J. Staal, L. Verstrepen, H. G. Tima, S. Terryn, M. Romano, K. Lemeire, V. Suin, A. Hamouda, M. Kalai, R. Beyaert, S. Van Gucht MALT1 Controls Attenuated Rabies Virus by Inducing Early Inflammation and T Cell Activation in the Brain published pages: , ISSN: 0022-538X, DOI: 10.1128/JVI.02029-17	Journal of Virology 92/8	2019-06-11

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "RABYD-VAX" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "RABYD-VAX" are provided by the European Opendata Portal: CORDIS opendata.